Literature DB >> 23677252

Primary Budd-Chiari syndrome in a 3-year-old boy with homozygous factor V Leiden G1691A mutation.

Aleksandra Boskovic1, Ivana Kitic, Ivica Stankovic, Dragan Prokic, Nada Zlatar.   

Abstract

UNLABELLED: Budd-Chiari syndrome (BCS) is an uncommon disorder characterized by obstruction of hepatic venous outflow. The primary BCS is a rare disease with an incidence about 0.2 per million inhabitants per year. We present a 3-year-old boy with intrahepatic inferior vena cava clot. Because of decreased levels of protein C (38.7 %), F II (69.1 %), and activated protein C resistance (1.43), a mutational gene analysis was performed. The patient was found to be homozygous for the FV G1691A mutation.
CONCLUSION: The primary BCS is a rare disease especially in childhood. Activated protein C resistance caused by the factor V Leiden mutation may be responsible for primary BCS. Prompt recognition of underlying prothrombotic disease and early initiation of their specific therapy might translate into rapid improvement of liver disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677252     DOI: 10.1007/s00431-013-2031-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

Review 1.  Budd-Chiari syndrome: a review by an expert panel.

Authors:  Harry L A Janssen; Juan-Carlos Garcia-Pagan; Elwyn Elias; Gilles Mentha; Antoine Hadengue; Dominique-Charles Valla
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

2.  Anticoagulant therapy and Budd-Chiari syndrome: is it successful?

Authors:  Filiz Akyüz; Yilmaz Cakaloğlu; Binnur Pinarbaşi; Kadir Demir; Umit Akyüz; Sadakat Ozdil; Fatih Beşişik; Güngör Boztaş; Zeynel Mungan; Sabahattin Kaymakoğlu
Journal:  Hepatogastroenterology       Date:  2011 May-Jun

3.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

4.  Transjugular intrahepatic portosystemic shunt (TIPSS) for Budd Chiari syndrome.

Authors:  R P Hasija; A Nagral; S Marar; A R Bavdekar
Journal:  Indian Pediatr       Date:  2010-06       Impact factor: 1.411

5.  Budd-Chiari syndrome in children and outcome after liver transplant.

Authors:  Ana Cristina Gomes; Gina Rubino; Carla Pinto; Augusta Cipriano; Emanuel Furtado; Isabel Gonçalves
Journal:  Pediatr Transplant       Date:  2012-03-27

6.  Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group.

Authors:  C Heller; R Schobess; K Kurnik; R Junker; G Günther; W Kreuz; U Nowak-Göttl
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

7.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

Review 8.  Primary Budd-Chiari syndrome.

Authors:  Dominique-Charles Valla
Journal:  J Hepatol       Date:  2008-10-26       Impact factor: 25.083

9.  High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)

Authors:  F R Rosendaal; T Koster; J P Vandenbroucke; P H Reitsma
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

10.  Clinical and laboratory evaluation of Turkish children with thrombosis for homozygous factor V G1691A mutation.

Authors:  Selma Unal; Gunay Balta; Feride Duru; Fatma Gumruk; Cigdem Altay; Aytemiz Gurgey
Journal:  Blood Coagul Fibrinolysis       Date:  2004-06       Impact factor: 1.276

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.